Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Kicks Off Biosimilars Week

Educational Resources Have Been Made Available By The Global Association

Executive Summary

A week-long global educational initiative to raise awareness of biosimilars has been launched by the IGBA.

You may also be interested in...



IGBA Launches Global Biosimilars Week 2021

The IGBA has followed the success of its inaugural Global Biosimilars Week in November 2020 by launching the second incarnation of the initiative, running this week.

First Interchangeability Designation Opens Doors For Biosimilars

An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.

‘Everything Cannot Be Locally Produced,’ Says IGBA Chair

In an exclusive interview with Generics Bulletin, IGBA chair Sudarshan Jain said that a resilient and diversified supply chain is critical, but localized production may not be the answer to everything. IGBA secretary general Suzette Kox and Jain discussed key lessons to be learned from COVID-19, the IGBA’s focus on regulatory harmonization, and challenges in driving the adoption of generics, biosimilars and value-added medicines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel